Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE · Healthcare · Biotechnology
$14.98+21.30%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.0B
- 52-week range
- $5.37 – $17.58
- 52-week change
- −16.67%
- EPS (trailing)
- −$5.06
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $170M (−25.05%)
- Net income
- −$313K
- Operating margin
- −185.3%
- Diluted EPS
- −$5.64
- Free cash flow
- −$179M
From the company’s annual report on SEC EDGAR.
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization.
Headquarters: Boston, United States · 485 employees · ginkgo.bio